repost: full text Angiogenesis Inhibitors: Current Strategies and Future Prospects

INHIBITOR OTHER NAMES INHIBITS Axitinib AG013736 VEGFR, PDGFR, and c-kit Canertinib CI-1033 EGFR, HER2, HER3, and HER4 Cediranib Recentin, AZD2171 VEGFR, PDGFR-, and c-kit Dasatinib Sprycel, BMS-354825 Abl, Src, and Tec Erlotinib Tarceva, OSI-774 EGFR/HER1 Gefitinib Iressa EGFR/HER1 Imatinib Gleevec, STI571 Abl, PDGFR, and c-kit Lapatinib Tykerb, GW-572016 EGFR and HER2 Leflunomide Arava, SU101 PDGFR (EGFR and FGFR) Motesanib AMG 706 VEGFR, PDGFR, and c-kit Neratinib HKI-272 EGFR and HER2 Nilotinib Tasigna Abl, PDGFR, and c-kit Pazopanib Armala, GW786034 VEGFR, PDGFR- and -, and c-kit Regorafenib BAY 73-4506 VEGFR-2 and Tie-2 Semaxinib SU5416 VEGFR Sorafenib Nexavar, BAY 43-9006 Raf, VEGFR-2 and -3, PDGFR-, and c-kit Sunitinib Sutent, SU11248 VEGFR, PDGFR, Flt-3, c-kit, RET, and CSF-1R Tandutinab MLN518, CT53518 PDGFR, Flt-3, and c-kit Toceranib Vandetanib Zactima, ZD6474 VEGFR-2, PDGFR-, EGFR, and RET Vatalanib PTK787 VEGFR, PDGFR-, and c-kit